Efficacy of Gefitinib for Brain Metastasis of Non-Small Cell Lung Cancer
Status:
Unknown status
Trial end date:
2010-12-01
Target enrollment:
Participant gender:
Summary
This is a non-randomized open-label uncontrolled phase II trial evaluating efficacy and
toxicity of gefitinib in patients with asymptomatic advanced NSCLC who was benefitted by
first line chemotherapy. Patients with stage IV NSCLC who have one or more asymptomatic brain
metastasis who was benefitted by first line chemotherapy will receive oral gefitinib 250mg
once daily until disease progression or unacceptable toxicity. These patients' direct DNA
sequencing of tumor tissue EGFR exons 18-21 will be analyzed The response was evaluated by
RECIST criteria after the patient received gefitinib 6 weeks.If the patients present with
progress disease of brain metastasis after the therapy of gefitinib, the patients will
receive irradiation of brain metastasis.If the response is stable disease,partial response or
complete response,he will be examined by brain MRI every 12 weeks.